Supernus Pharma (SUPN) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Supernus Pharma (SUPN) Misses Q1 EPS by 1c

Supernus Announces First Quarter 2016 Financial Results

May 3, 2016 5:00 PM EDT

First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter of 2015.Operating income for first quarter 2016 was $5.3 million, a 55.0% increase over the first quarter of 2015.   Diluted earnings per share in the first quarter were $0.08 compared to $0.02 in the same period last year.   The Company remains on track to have data available from the Phase III program for SPN-810, for the treatment of Impulsive Aggression in ADHD, by mid-2017 and from the Phase IIb program for... More